clinical trial · NCT07253207
Efficacy and Safety Study of Levomilnacipran Hydrochloride Extended-Release Capsules in Major Depressive Disorder
Zhejiang Huahai Pharmaceutical Co., Ltd.·phase3·completed·n = 392
Major Depressive Disorder (MDD)Levomilnacipran Hydrochloride Extended-Release CapsulesDuloxetine Hydrochloride Enteric Capsules
brief summary
The purpose of this study is using Duloxetine Hydrochloride Enteric Capsules as the positive control, to evaluate the efficacy and safety of Levomilnacipran Hydrochloride Extended-Release Capsules in patients with Major Depressive Disorder (MDD).
started
Oct 17, 2024
primary completion
Jun 13, 2025
completion
Jul 22, 2025
last updated
Nov 28, 2025
official title
A Randomized, Double-Blind, Active-Controlled, Multicenter Phase III Clinical Trial Evaluating the Efficacy and Safety of Levomilnacipran Hydrochloride Extended-Release Capsules in the Treatment of Patients With Major Depressive Disorder (MDD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol